samedan logo
 
 
spacer
home > epc > spring 2009 > centralising ecgs
PUBLICATIONS
European Pharmaceutical Contractor

Centralising ECGs

Cardiac safety has become the number one reason for drug withdrawals and labelling changes during the past several years. This has resulted in greater regulatory scrutiny for all new compounds and greater concern among pharmaceutical companies in regard to the potential effect of their compounds on cardiac safety. One of the outcomes of this focus was the ICH E14 document, which provided guidance on the conduct of a dedicated ECG study which many term the ‘thorough QT (TQT) trial’ (1). These trials are generally conducted after proof of concept has been completed and employ digital and centralised ECGs as described in E14. However, although  almost all TQT trials are centralised, only approximately 20 to 25 per cent of all other clinical research (Phases I-IV) trials use centralised ECG analyses.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Jeffrey S Litwin is a board certified Internist and Cardiologist. He left his cardiology practice in 1988 to serve as Director, Medical Affairs at Wyeth-Ayerst Laboratories. Jeffrey has been providing consultative support to the pharmaceutical industry for the design and conduct of cardiac safety trials and to the device industry for the design of ECG and Holter technologies for over 15 years. He is currently an Executive Vice President and the Chief Medical Officer for eResearchTechnology ERT), which he joined in July, 2000.

spacer
Jeffrey S Litwin
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Clinical Trial Logistics

17-18 May 2010, London, UK

This year’s conference will provide you with the tools necessary to effectively manage your supply chain and ensure that your trials complete on time and within budget. This conference will also analyse the latest developments in labelling, packaging, inventory management, security, forecasting, partnering and outsourcing.
More info >>

 
News and Press Releases

2010 BIO International Convention Expected to Bring More Than $25 Million to Chicago

The Biotechnology Industry Organization announced today that the 2010 BIO International Convention is expected to contribute more than $25 million to the local economy, according to estimates from the Chicago Convention and Tourism Bureau. The BIO International Convention returns to Chicago on 3rd-6th May and is expected to draw 15,000 to 17,000 industry leaders from 48 states and 60 countries.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement